IMIC(SZ:000516) Sou Hu Cai Jing·2025-05-06 08:28Core Viewpoint - The company International Medical has reported a decline in revenue and net profit for Q1 2025, indicating potential challenges in its financial performance despite holding a significant market position in the healthcare sector [1]. Group 1: Company Overview - International Medical's closing stock price on May 6 was 5.11 yuan, reflecting a 1.39% increase, with a latest price-to-book ratio of 3.24 and a total market capitalization of 11.551 billion yuan [1]. - As of Q1 2025, a total of 10 institutions hold shares in International Medical, including 5 other entities, 4 funds, and 1 brokerage, with a combined holding of 75,944.78 million shares valued at 4.139 billion yuan [1]. - The company's main business focuses on health services and the application of modern medical technology, with key products spanning healthcare, software and IT services, social services, and commodity circulation [1]. Group 2: Financial Performance - For Q1 2025, International Medical reported an operating revenue of 999.7 million yuan, representing a year-on-year decline of 14.99% [1]. - The net profit for the same period was -106,353,858.88 yuan, showing a year-on-year decrease of 1.37%, with a sales gross margin of 5.21% [1]. Group 3: Industry Comparison - The company has a trailing twelve months (TTM) price-to-earnings (PE) ratio of -45.20, which is significantly lower than the industry average of 38.66 [2]. - The industry median PE ratio stands at 38.36, indicating that International Medical is underperforming compared to its peers [2].